Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study

Table 4 Concurrent Chemotherapy-Related Adverse Events

NCI-CTC^a (Grade)	Patients
	All		LC		CRC		Other
	(n = 28)		(n = 13^b)		(n = 10)		(n = 5)
Adverse event	1–2	≥3	1–2	≥3	1–2	≥3	1–2	≥3
Hematological toxicity, number of cases
Leukocytopenia	7	8	4	6	3	1	2	1
Neutropenia	5	14	1	9	2	3	2	2
Anemia	20	2	9	2	8	0	3	0
Thrombocytopenia	3	3	1	2	1	1	1	0
Lymphopenia	13	10	4	8*	7	1	2	1
Non-hematological toxicity, number of cases
AST/ALT elevation	12	0	4	0	6	0	2	0
Interstitial pneumonitis	0	1^c	0	1^c	0	0	0	0
Colitis	0	1^d	0	0	0	0	0	1^d
Anaphylaxis	0	2^e	0	0	0	2^e	0	0
Hemorrhage	1^f	1^g	1^f	0	0	1^g	0	0

ISSN: 1471-2407